Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnolo… Read more
Beijing Leadman Biochemistry Co Ltd (300289) - Net Assets
Latest net assets as of September 2025: CN¥1.71 Billion CNY
Based on the latest financial reports, Beijing Leadman Biochemistry Co Ltd (300289) has net assets worth CN¥1.71 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.81 Billion) and total liabilities (CN¥96.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.71 Billion |
| % of Total Assets | 94.67% |
| Annual Growth Rate | 20.77% |
| 5-Year Change | 24.65% |
| 10-Year Change | 36.4% |
| Growth Volatility | 58.64 |
Beijing Leadman Biochemistry Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Beijing Leadman Biochemistry Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Leadman Biochemistry Co Ltd (2008–2024)
The table below shows the annual net assets of Beijing Leadman Biochemistry Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.72 Billion | -4.77% |
| 2023-12-31 | CN¥1.80 Billion | +1.36% |
| 2022-12-31 | CN¥1.78 Billion | -9.99% |
| 2021-12-31 | CN¥1.98 Billion | +43.48% |
| 2020-12-31 | CN¥1.38 Billion | -4.92% |
| 2019-12-31 | CN¥1.45 Billion | +0.87% |
| 2018-12-31 | CN¥1.44 Billion | +0.86% |
| 2017-12-31 | CN¥1.43 Billion | +6.62% |
| 2016-12-31 | CN¥1.34 Billion | +6.09% |
| 2015-12-31 | CN¥1.26 Billion | +15.30% |
| 2014-12-31 | CN¥1.09 Billion | +28.38% |
| 2013-12-31 | CN¥851.12 Million | +11.84% |
| 2012-12-31 | CN¥761.02 Million | +244.71% |
| 2011-12-31 | CN¥220.77 Million | +38.22% |
| 2010-12-31 | CN¥159.72 Million | +51.65% |
| 2009-12-31 | CN¥105.32 Million | +25.52% |
| 2008-12-31 | CN¥83.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Leadman Biochemistry Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 707.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥432.39 Million | 26.01% |
| Common Stock | CN¥544.01 Million | 32.73% |
| Other Components | CN¥685.69 Million | 41.25% |
| Total Equity | CN¥1.66 Billion | 100.00% |
Beijing Leadman Biochemistry Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Leadman Biochemistry Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korea Line
KO:005880
|
$267.14 Million |
|
Abacus Group
AU:ABG
|
$267.17 Million |
|
Ranger Energy Services Inc
NYSE:RNGR
|
$267.18 Million |
|
Energiekontor AG
F:EKT
|
$267.18 Million |
|
FocalTech Systems Co Ltd
TW:3545
|
$267.03 Million |
|
Everjoy Health Group Co Ltd
SHE:002162
|
$267.02 Million |
|
Allied Blenders & Distillers Ltd
NSE:ABDL
|
$266.98 Million |
|
Samhyun
KQ:437730
|
$266.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Leadman Biochemistry Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,742,642,071 to 1,662,100,621, a change of -80,541,450 (-4.6%).
- Net loss of 75,101,335 reduced equity.
- Dividend payments of 5,440,114 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-75.10 Million | -4.52% |
| Dividends Paid | CN¥5.44 Million | -0.33% |
| Other Changes | CN¥-1.00 | -0.0% |
| Total Change | CN¥- | -4.62% |
Book Value vs Market Value Analysis
This analysis compares Beijing Leadman Biochemistry Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 23.08x to 2.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.30 | CN¥6.81 | x |
| 2009-12-31 | CN¥0.37 | CN¥6.81 | x |
| 2010-12-31 | CN¥0.55 | CN¥6.81 | x |
| 2011-12-31 | CN¥0.76 | CN¥6.81 | x |
| 2012-12-31 | CN¥2.08 | CN¥6.81 | x |
| 2013-12-31 | CN¥2.23 | CN¥6.81 | x |
| 2014-12-31 | CN¥2.48 | CN¥6.81 | x |
| 2015-12-31 | CN¥2.94 | CN¥6.81 | x |
| 2016-12-31 | CN¥3.03 | CN¥6.81 | x |
| 2017-12-31 | CN¥3.05 | CN¥6.81 | x |
| 2018-12-31 | CN¥3.11 | CN¥6.81 | x |
| 2019-12-31 | CN¥3.15 | CN¥6.81 | x |
| 2020-12-31 | CN¥3.02 | CN¥6.81 | x |
| 2021-12-31 | CN¥4.09 | CN¥6.81 | x |
| 2022-12-31 | CN¥3.18 | CN¥6.81 | x |
| 2023-12-31 | CN¥3.41 | CN¥6.81 | x |
| 2024-12-31 | CN¥3.10 | CN¥6.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Leadman Biochemistry Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.29%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.10x
- Recent ROE (-4.52%) is below the historical average (11.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 31.18% | 25.20% | 0.91x | 1.36x | CN¥17.77 Million |
| 2009 | 39.32% | 28.91% | 0.94x | 1.45x | CN¥30.88 Million |
| 2010 | 34.06% | 29.31% | 0.72x | 1.62x | CN¥38.43 Million |
| 2011 | 32.55% | 28.50% | 0.69x | 1.66x | CN¥49.77 Million |
| 2012 | 12.92% | 30.98% | 0.28x | 1.49x | CN¥22.19 Million |
| 2013 | 12.93% | 32.03% | 0.28x | 1.46x | CN¥24.96 Million |
| 2014 | 13.30% | 23.89% | 0.33x | 1.68x | CN¥31.83 Million |
| 2015 | 13.25% | 23.06% | 0.41x | 1.40x | CN¥38.52 Million |
| 2016 | 5.61% | 13.06% | 0.32x | 1.34x | CN¥-54.52 Million |
| 2017 | 5.58% | 12.69% | 0.33x | 1.34x | CN¥-57.95 Million |
| 2018 | 3.09% | 6.18% | 0.38x | 1.32x | CN¥-90.58 Million |
| 2019 | 0.48% | 1.22% | 0.30x | 1.30x | CN¥-125.37 Million |
| 2020 | -4.04% | -10.81% | 0.29x | 1.29x | CN¥-177.15 Million |
| 2021 | 1.22% | 3.97% | 0.24x | 1.28x | CN¥-161.08 Million |
| 2022 | -3.26% | -7.97% | 0.35x | 1.16x | CN¥-229.00 Million |
| 2023 | 0.88% | 3.32% | 0.24x | 1.11x | CN¥-158.93 Million |
| 2024 | -4.52% | -20.29% | 0.20x | 1.10x | CN¥-241.31 Million |
Industry Comparison
This section compares Beijing Leadman Biochemistry Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,928,877,660
- Average return on equity (ROE) among peers: 27.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Leadman Biochemistry Co Ltd (300289) | CN¥1.71 Billion | 31.18% | 0.06x | $267.10 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |